12.3 Severe Anemias, Hemolytic Syndromes & Transfusion Complications

12.3 Severe Anemias, Hemolytic Syndromes & Transfusion Complications

Clinical Scenario: A 71-year-old male with ischemic heart failure receives two units of packed red blood cells for symptomatic anemia (hemoglobin 6.8 g/dL). Midway through unit two, he develops acute tachypnea, agitation, and hypoxia (SpO2 84%). Vital signs: BP 184/102 mmHg (baseline 122/74 mmHg), HR 118 bpm, temperature 37.0°C. Examination reveals jugular venous distention, bilateral coarse crackles, an S3 gallop, and pink frothy sputum. The acute care nurse practitioner must differentiate hydrostatic volume overload (TACO) from permeability edema (TRALI) and intervene immediately.

Pulmonary Transfusion Emergencies: TRALI vs. TACO

Pulmonary complications are the leading cause of transfusion-related mortality. Differentiating Transfusion-Related Acute Lung Injury (TRALI) from Transfusion-Associated Circulatory Overload (TACO) is vital because their management pathways are diametrically opposed.

• TRALI (Non-Cardiogenic Permeability Edema): Two-hit model. Hit 1: Recipient inflammation primes endothelial cells and sequesters neutrophils in lungs. Hit 2: Transfused donor anti-HLA or anti-HNA antibodies bind and activate primed recipient neutrophils. This releases proteases and reactive oxygen species, producing capillary leak and severe non-cardiogenic pulmonary edema within 6 hours.
• TACO (Hydrostatic Cardiogenic Edema): Acute hydrostatic volume overload where transfusion rate or volume exceeds cardiopulmonary capacity. Elevated left ventricular filling pressures transmit retrogradely into pulmonary capillaries, forcing transudative fluid across alveolar membranes. Risk factors include heart failure, renal disease, aortic stenosis, and age >65 years.

Comprehensive Diagnostic Differentiation

Management Protocols

• TRALI Protocol: Stop transfusion immediately; maintain IV access with $0.9\%\text{ NaCl}$; provide lung-protective mechanical ventilation ($6\text{ mL/kg}$ PBW, PEEP titration, plateau pressure $\le 30\text{ cmH}_2\text{O}$); administer cautious IV crystalloids or norepinephrine for hypotension. Avoid diuretics. Immediately notify blood bank to quarantine donor components and test HLA/HNA antibodies.
• TACO Protocol: Stop transfusion immediately; place patient fully upright ($90^\circ$); administer oxygen or Non-Invasive Positive Pressure Ventilation (CPAP/BiPAP); give IV loop diuretics (furosemide $20–80\text{ mg IV}$); infuse nitroglycerin for refractory hypertension. Future transfusions require split units infused slowly ($\le 1\text{ mL/kg/hr}$) with pre-transfusion furosemide.

Acute Hemolytic Transfusion Reaction (AHTR)

AHTR is an emergency caused by ABO incompatibility from clerical errors.

• Pathophysiology: Preformed recipient IgM antibodies bind donor red cells, activating complement (intravascular hemolysis via C5b-9). Anaphylatoxins (C3a, C5a) cause histamine release, bronchospasm, and shock. Exposed erythrocyte stroma activates factor XII, triggering DIC. Free hemoglobin precipitates as ferrihemate casts in acidic tubules, causing acute tubular necrosis.
• Clinical Signs: Abrupt fever, chills, chest tightness, severe bilateral flank/back pain, hypotension, hemoglobinuria (burgundy urine), and line oozing.
• Immediate Bedside Actions:
  1. Stop transfusion immediately and disconnect infusion tubing at catheter hub.
  2. Maintain IV access with fresh tubing infusing $0.9\%\text{ NaCl}$.
  3. Re-check patient wristband against unit tags and crossmatch documents.
  4. Notify blood bank; return blood bag, tubing, and IV solutions.
  5. Draw post-reaction blood (clotted and EDTA for repeat crossmatch, typing, and DAT) and send first urine specimen for free hemoglobin.
  6. Aggressively infuse isotonic saline to maintain MAP $\ge 65\text{ mmHg}$ and urine output $\ge 1.0–2.0\text{ mL/kg/hr}$ to flush casts.

Massive Transfusion Complications: The Lethal Derangements

Massive transfusion ($\ge 10$ units PRBCs in 24 hr, $\ge 4$ units in 1 hr, or $>50\%$ blood volume in 3 hr) utilizes a balanced 1:1:1 ratio (PRBCs:FFP:platelets) to prevent dilutional coagulopathy. Clinicians must actively monitor for metabolic sequelae:

1. Citrate Toxicity & Ionized Hypocalcemia: Sodium citrate anticoagulant binds free calcium. Rapid infusion overwhelms hepatic clearance (worsened by hypothermia/shock). Ionized hypocalcemia ($<0.9\text{ mmol/L}$) impairs contractility, causes hypotension, prolongs QTc, and halts coagulation (Factor IV). Action: Check ionized calcium every 4 units PRBCs; administer $1–2\text{ g}$ IV calcium chloride (10%) via central line (or $3\text{ g}$ calcium gluconate peripherally) targeting $\text{iCa}^{2+} >1.12\text{ mmol/L}$.
2. Hyperkalemia: Extracellular potassium in stored PRBCs reaches $30–50\text{ mEq/L}$ from membrane leakage. Rapid infusion triggers peaked T waves, QRS widening, and arrhythmias; treat with IV calcium, insulin/dextrose, and albuterol.
3. Hypothermia: Transfusing cold blood ($4^\circ\text{C}$) reduces clotting enzyme activity by $10\%$ per $1^\circ\text{C}$ drop. Use rapid fluid warmers; maintain core temperature $>36.0^\circ\text{C}$.
4. Acidosis & Dilutional Coagulopathy: Banked blood pH is ~6.5. Manage with balanced 1:1:1 transfusion and thromboelastography (TEG/ROTEM).

Thrombotic Microangiopathies: Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a medical emergency caused by severe deficiency of ADAMTS13 activity ($<10\%$), a metalloproteinase cleaving ultra-large von Willebrand factor (ULVWF) multimers. In acquired TTP, an IgG autoantibody inhibits ADAMTS13. Uncleaved multimers trigger spontaneous platelet aggregation under high shear stress, forming occlusive platelet-rich microthrombi in brain, heart, and kidney microvessels.

• MAHA: RBC shearing through platelet meshes produces schistocytes ($>1–2\%$ on smear), elevated LDH, undetectable haptoglobin, and indirect hyperbilirubinemia.
• Diagnostic Pentad: (1)MAHA with schistocytes, (2)thrombocytopenia, often<30,000/µL, (3) fluctuating neurological signs (confusion, aphasia, seizures, stroke; ~65%), (4) renal impairment (hematuria, elevated creatinine; ~50%), and (5) fever (<25%).
• TTP vs. DIC: PT/aPTT and fibrinogen are usually normal in TTP, supporting a platelet-rich microangiopathy. Normal results do not exclude early DIC; interpret serial tests and the clinical setting. Send ADAMTS13 activity/inhibitor samples before plasma treatment, but do not delay PLEX and steroids when TTP probability is high.
• Emergency Interventions:
  1. Therapeutic Plasma Exchange (PLEX): Standard of care. Daily 1.0–1.5 plasma volume exchange with FFP removes autoantibodies/multimers and replenishes ADAMTS13. Continue until platelets $>150,000/\mu\text{L}$ and LDH normalizes $\ge 2$ days.
  2. Corticosteroids: Methylprednisolone $1.0\text{ g IV}$ daily for 3 days to halt antibody synthesis.
  3. Caplacizumab: Anti-VWF nanobody ($10\text{ mg IV}$ bolus, then $10\text{ mg SC}$ daily post-PLEX) blocking VWF-platelet GPIb interaction.
  4. Rituximab: $375\text{ mg/m}^2$ weekly for 4 doses to eliminate autoreactive B cells.
  5. Platelet Transfusion: Avoid routine prophylactic platelets in nonbleeding TTP; serious bleeding or a high-risk procedure requires specialist assessment.